Metsera Announces Positive Phase 2b Results for MET-097i
Placebo-subtracted mean weight loss of up to 14.1% was observed after 28 weeks with MET-097i, showcasing its potential to be a frontrunner in obesity treatment. Additionally, the data suggests that there is no plateau in weight loss, a promising sign for potential long-term efficacy.
The drug also exhibited high tolerability with minimal adverse effects, including only a 13% incidence of nausea and 11% vomiting across both VESPER-1 and VESPER-3 trials. These encouraging findings support the likelihood of advancing MET-097i into Phase 3 clinical trials by late 2025, as indicated by Metsera, Inc. (Nasdaq: MTSR).
Overview of MET-097i Development
MET-097i is a unique, fully biased, ultra-long acting GLP-1 receptor agonist designed for ease of use with potential monthly dosing. In the VESPER-1 trial, consisting of 239 participants, MET-097i demonstrated a significant body weight reduction, presenting a collaborative opportunity for weight management. Various doses, ranging from 0.4 mg to 1.2 mg, were tested over a period of 28 weeks without the need for titration.
Results from VESPER-1 revealed positive weight loss outcomes characterized by a dose-dependent response. The 1.2 mg dose resulted in a remarkable placebo-subtracted mean weight loss of 14.1% at 28 weeks. Exploratory analysis indicated continued weight loss, suggesting that participants did not experience a plateau effect after the dosing period.
Clinical Trial Insights
The outcomes from both VESPER-1 and the interim results from VESPER-3 also highlighted MET-097i's favorable safety profile, mimicking tolerability observed with placebo. With a 2.9% study discontinuation rate primarily due to adverse events, MET-097i exhibited a robust retention rate among participants, indicative of the treatment’s acceptability.
Results Supporting Future Clinical Trials
The interim analysis from VESPER-3, enrolling 268 participants, provides critical insights into the tolerability of MET-097i following a two-step titration approach. Even at elevated doses, adverse effects such as diarrhea were minimal. Such results are essential for optimizing future treatment plans and ensuring participant comfort during trials.
Next Steps in MET-097i Development
Metsera envisions launching a global Phase 3 program to assess long-term efficacy and safety. Ongoing Phase 2b studies will delve into how MET-097i performs in diverse patient populations, including those with type 2 diabetes mellitus. Notably, the VESPER-2 study will also focus on evaluating MET-097i’s performance for this critical demographic, with expectations to announce topline data in the near future.
About MET-097i and Its Role in Obesity Treatment
MET-097i serves as the foundation for several innovative programs aimed at furthering Metsera's mission of tackling obesity and metabolic disorders. Notable future initiatives include multimodal combination therapies that integrate their proprietary HALO™ platform, engineered for enhanced peptide stability and extended half-life. This positioning places MET-097i at the forefront of next-generation therapies.
As the obesity epidemic continues to escalate, the development of effective medications like MET-097i is more critical than ever. Metsera’s commitment to advancing these solutions signifies significant movement within the biopharmaceutical landscape for obesity treatments.
Frequently Asked Questions
What are the main findings from the VESPER-1 and VESPER-3 trials?
The trials indicated a placebo-subtracted weight loss of up to 14.1% with favorable tolerability and minimal adverse effects.
When does Metsera plan to advance MET-097i to Phase 3 trials?
The initiation of Phase 3 trials is expected in late 2025, based on current positive topline data.
What patient populations are targeted in ongoing MET-097i trials?
The trials are primarily focused on individuals dealing with overweight or obesity, with some studies assessing efficacy in participants with type 2 diabetes.
How does MET-097i compare to other obesity treatments?
MET-097i is designed to offer class-leading weight loss outcomes at lower doses compared to current market leaders, with anticipated monthly dosing to enhance patient compliance.
What technology underpins the MET-097i platform?
Metsera utilizes its HALO™ peptide stabilization and lipidation platform, facilitating extended half-life and effectiveness of the therapy.
